Table 1 Cardiovascular risk factors, clinical data and medication (n (%) or median [IQR]) (n = 284)
metformin | Metformin n = 119 | No Metformin n = 165 | p value |
|---|---|---|---|
Risk factors | |||
 Age ≥ 65 years | 28 (23.5%) | 46 (27.9%) | 0.410 |
 Women | 26 (21.8%) | 47 (28.5%) | 0.207 |
 Diabetes duration≥5 years | 80 (67.2%) | 99 (60.0%) | 0.430 |
 Hypertension | 74 (62.2%) | 114 (69.1%) | 0.225 |
 Hyperlipidemia | 53 (44.5%) | 61 (37.0%) | 0.199 |
 Current smoking | 80 (67.2%) | 99 (60.0%) | 0.213 |
 Stroke | 8 (6.7%) | 14 (8.5%) | 0.586 |
 Prior myocardial infarction | 16 (13.4%) | 12 (7.3%) | 0.085 |
 PAD | 3 (2.5%) | 4 (2.4%) | 0.959 |
Medical therapy initiated during hospitalization | |||
 Other oral antihyperglycemic agent. | 60 (50.4%) | 73 (44.2%) | 0.303 |
 ACEI or ARB | 51 (42.9%) | 68 (41.2%) | 0.782 |
 Mineralocorticoid receptor antagonist | 4 (3.4%) | 7 (4.2%) | 0.946 |
 Calcium-channel blocker | 6 (5.0%) | 5 (3.0%) | 0.579 |
 Beta-blocker | 95 (79.8%) | 99 (60%) | < 0.05 |
Metformin dosage | Â | Â | 0.230 |
  > 0 g to ≤0.5 g | 1 (0.8%) | 7 (4.2%) |  |
  > 0.5 g to ≤1 g | 32 (26.9%) | 36 (21.8%) |  |
  > 1 g to ≤1.5 g | 85 (71.4%) | 118 (71.5%) |  |
  > 1.5 g | 1 (0.8%) | 4 (2.4%) |  |
Clinical data | |||
 LVEF≤40% | 7 (5.9%) | 11 (6.7%) | 0.789 |
 Time to PCI (hour) | 4 (6–16) | 6 (4–9) | 0.139 |
 Single--vessel disease | 31 (26.1%) | 45 (27.3%) | 0.818 |
Infarct-related artery | |||
 Left main | 0 (0%) | 1 (0.6%) | 1.000 |
 Left anterior descending coronary artery | 56 (47.1%) | 83 (50.3%) | 0.589 |
 Left circumflex coronary artery | 17 (14.3%) | 20 (12.1%) | 0.593 |
 Right coronary artery | 47 (39.5%) | 60 (36.4%) | 0.591 |
 Contrast media volume (ml) | 120 (120–200) | 150 (110–200) | 0.884 |